Biopharmaceutical company AbbVie (NYSE:ABBV) on Tuesday announced a consent decree agreement with staff of the US Federal Trade Commission (FTC) regarding the proposed acquisition of Allergan plc (NYSE:AGN) in May 2020.

Pursuant to the consent decree, the parties have agreed to sell brazikumab that is in development for autoimmune diseases to AstraZeneca and Zenpep, a treatment for exocrine pancreatic insufficiency due to cystic fibrosis and other conditions to Nestle. Additionally, Nestle will acquire Viokace, another pancreatic enzyme preparation,

The consent decree, including the proposed purchasers, remains subject to further review and approval by the Commissioners of the FTC.

Headquartered in Dublin, Ireland, Allergan plc is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. It markets a portfolio of leading brands primarily focused on medical aesthetics, eye care, central nervous system and gastroenterology.

ZENPEP (pancrelipase) is a prescription medication that contains a mixture of digestive enzymes (lipases, proteases, and amylases) from pig pancreas. Brazikumab is a monoclonal antibody that selectively blocks the IL23 immune signal, preventing intestinal inflammation, concluded the companies.